4.19
price down icon1.64%   -0.07
after-market After Hours: 4.19
loading
Vanda Pharmaceuticals Inc stock is traded at $4.19, with a volume of 767.00K. It is down -1.64% in the last 24 hours and down -10.47% over the past month. Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$4.26
Open:
$4.25
24h Volume:
767.00K
Relative Volume:
1.59
Market Cap:
$246.94M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
79.96
EPS:
0.0524
Net Cash Flow:
$12.42M
1W Performance:
-11.60%
1M Performance:
-10.47%
6M Performance:
-4.99%
1Y Performance:
-25.71%
1-Day Range:
Value
$4.16
$4.265
1-Week Range:
Value
$4.16
$4.89
52-Week Range:
Value
$3.8092
$5.56

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name
Name
Vanda Pharmaceuticals Inc
Name
Phone
202-734-3400
Name
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Name
Employee
368
Name
Twitter
Name
Next Earnings Date
2025-05-02
Name
Latest SEC Filings
Name
VNDA's Discussions on Twitter

Compare VNDA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VNDA
Vanda Pharmaceuticals Inc
4.19 251.06M 192.64M 2.51M 12.42M 0.0524
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-31-24 Initiated H.C. Wainwright Buy
Jul-11-24 Initiated Cantor Fitzgerald Overweight
Feb-25-22 Downgrade Jefferies Buy → Hold
May-12-21 Initiated BofA Securities Buy
Jan-14-21 Downgrade Citigroup Buy → Neutral
Oct-29-20 Upgrade Citigroup Neutral → Buy
Jun-09-20 Downgrade Citigroup Buy → Neutral
Mar-16-20 Downgrade Oppenheimer Perform → Underperform
Mar-12-20 Upgrade Citigroup Neutral → Buy
Nov-07-19 Downgrade Citigroup Buy → Neutral
Aug-01-19 Upgrade Citigroup Neutral → Buy
Jul-25-19 Downgrade Stifel Buy → Hold
Dec-11-18 Downgrade Oppenheimer Outperform → Perform
Dec-04-18 Upgrade Cantor Fitzgerald Neutral → Overweight
Dec-04-18 Reiterated Jefferies Buy
Nov-08-18 Resumed Jefferies Buy
Sep-21-18 Resumed Oppenheimer Outperform
May-23-18 Initiated Citigroup Buy
Jan-19-18 Initiated Seaport Global Securities Buy
Sep-14-17 Reiterated Piper Jaffray Overweight
Jun-27-17 Resumed Piper Jaffray Overweight
May-26-17 Initiated H.C. Wainwright Buy
Apr-12-17 Initiated Oppenheimer Outperform
Nov-09-16 Initiated Aegis Capital Buy
Oct-06-16 Resumed Jefferies Buy
View All

Vanda Pharmaceuticals Inc Stock (VNDA) Latest News

pulisher
08:29 AM

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2025 Earnings Call Transcript - Insider Monkey

08:29 AM
pulisher
04:18 AM

Vanda (VNDA) Q2 Revenue Rises 4% - The Motley Fool

04:18 AM
pulisher
02:33 AM

Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising ... By GuruFocus - Investing.com Canada

02:33 AM
pulisher
02:13 AM

Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising Expenses - GuruFocus

02:13 AM
pulisher
01:11 AM

Vanda Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks

01:11 AM
pulisher
01:09 AM

Vanda Pharmaceuticals 2025 Q2 Earnings Misses Targets as Net Loss Widens 502% - AInvest

01:09 AM
pulisher
12:46 PM

Vanda: Q2 Earnings Snapshot - Norwalk Hour

12:46 PM
pulisher
Jul 31, 2025

What are Vanda Pharmaceuticals Inc. company’s key revenue driversBreakout Stocks Opportunities That Work - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

Vanda Pharmaceuticals' Q2 2025: Navigating Contradictions in Bysanti, PONVORY, and DTC Strategies - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Vanda Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat

Jul 31, 2025
pulisher
Jul 31, 2025

Earnings call transcript: Vanda Pharmaceuticals Q2 2025 misses EPS and revenue forecasts - Investing.com

Jul 31, 2025
pulisher
Jul 31, 2025

Vanda Pharmaceuticals: Navigating Q2 Earnings Disappointment Amid High-Stakes Pipeline Progress - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Vanda Pharmaceuticals Sees Strong Fanapt Growth Despite Rising Losses - Finimize

Jul 31, 2025
pulisher
Jul 31, 2025

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

Vanda Pharmaceuticals' Q2 2025 Earnings: A Turning Point in Pipeline Execution and Commercialization - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results - PR Newswire

Jul 31, 2025
pulisher
Jul 31, 2025

How volatile is Vanda Pharmaceuticals Inc. stock compared to the marketMarket Forecast Data Feed Backed By Experts - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 30, 2025

Exploring US High Growth Tech Stocks For Potential Portfolio Expansion - simplywall.st

Jul 30, 2025
pulisher
Jul 29, 2025

How Vanda Pharmaceuticals Inc. stock performs during market volatilityExit Ready Momentum Stock Watchlist Expanded - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Price Channel Expanding on Vanda Pharmaceuticals Inc.’s ChartROI Boosting Trade Opportunity Calendar Published - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Bronstein, Gewirtz & Grossman, LLC Class Action Update Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH) - ACCESS Newswire

Jul 29, 2025
pulisher
Jul 29, 2025

Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire

Jul 29, 2025
pulisher
Jul 28, 2025

How many analysts rate Vanda Pharmaceuticals Inc. as a “Buy”Overwhelming profit margins - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Should I hold or sell Vanda Pharmaceuticals Inc. stock in 2025Free Trading Psychology Coaching - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Vanda Pharmaceuticals Inc. generate profit in a changing economyBuild a diversified portfolio for stability - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionRapid Gain Targets - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

Is Vanda Pharmaceuticals Inc. a growth stock or a value stockAchieve superior returns with professional insights - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What institutional investors are buying Vanda Pharmaceuticals Inc. stockAchieve consistent profits with disciplined trading - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

Is Vanda Pharmaceuticals Inc. a good long term investmentRapid wealth accumulation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

When is the best time to buy Vanda Pharmaceuticals Inc. stockPowerful profit generation - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 - Barchart.com

Jul 24, 2025
pulisher
Jul 23, 2025

Vanda Pharmaceuticals Inc. Stock Analysis and ForecastSkyrocketing investment returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Vanda Pharmaceuticals Inc. stockAccelerated capital growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Vanda Pharmaceuticals Schedules Q2 Earnings Call: Key Financial Updates Coming July 31 - Stock Titan

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Vanda Pharmaceuticals Inc. stock priceMassive profits - jammulinksnews.com

Jul 22, 2025

Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Cap:     |  Volume (24h):